InMed Pharmaceuticals looks to take cannabinoid-based research to the next level

InMed Pharmaceuticals Inc (TSE:IN; OTCMKTS:IMLFF) released results Thursday for the company’s fourth quarter of fiscal 2018, including the three and twelve months ended June 30, 2018. 

Shares were down 8.98% at US$0.64 in New York and down 9.78% at C$0.83 in Toronto. 

For the three and 12 months ended June 30, 2018, the company recorded a net loss of C$3.03 million and C$8.52 million, or C$0.02 and C$0.06 per share, respectively, compared with a net loss of C$1.88 million and C$4.47 million, or C$0.02 and C$0.05 per share, for the three and twelve months ended June 30, 2017.

“During the

...read more at http://www.proactiveinvestors.com/companies/news/204872/inmed-pharmaceuticals-looks-to-take-cannabinoid-based-research-to-the-next-level-204872.html

by